Brendan Teehan - Feb 23, 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, COO, HEAD OF COMMERCIAL
Signature
/s/ Jennifer J. Rhodes, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Feb 23, 2024
Transactions value $
-$15,394
Form type
4
Date filed
2/27/2024, 06:10 PM
Previous filing
Jan 9, 2024
Next filing
Mar 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise +1.11K +3.58% 32.1K Feb 23, 2024 Direct F1
transaction ACAD Common Stock Sale -$15.4K -624 -1.95% $24.67 31.4K Feb 26, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -1.11K -50% $0.00 1.11K Feb 23, 2024 Common Stock 1.11K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
F3 The restricted stock units vest in four equal annual installments beginning February 23, 2022.